“We need all stakeholders to be all in on biosimilars…now’s the time for people to get engaged and get out there to support uptake and access,” says our guest, Juliana Reed, president of Biosimilars Forum.
Last week on the podcast, we brought you an industry perspective on biosimilars with a discussion of how manufacturers think about pricing their products for the marketplace. This week, we’re changing gears with a discussion of how that marketplace is working.
Our guest this week is Juliana Reed, president of Biosimilars Forum.
The Biosimilars Forum is a nonprofit organization that seeks to raise awareness of biosimilars and provide an opportunity for developers to work together with other stakeholders on relevant topics in the industry. The founding members of the Biosimilars Forum include many of the companies with significant US biosimilar development portfolios.
Reed joined The Center for Biosimilars® by phone to discuss reimbursement, policy, and what it takes to create a vibrant marketplace for cost-saving biosimilars.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlighted key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
AAM's Craig Burton: Is the Biden Administration Doing Enough to Help Biosimilars?
November 13th 2022Craig Burton, senior vice president of policy and strategic alliances at the Association for Accessible Medicines and executive director of the Biosimilars Council, gives insight into the many health policies that the Biden administration has implemented in 2022 as well as their possible impact on biosimilar adoption.
How Health Policy Can Impact Adoption for Adalimumab Biosimilars
September 25th 2022In this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, discussed current policy initiatives that could help biosimilar adoption and how the Inflation Reduction Act is expected to influence the adalimumab market.